Component

Hepatic glucose production / endogenous glucose production

Hepatic glucose production / endogenous glucose production. Species, exposure and limitations are retained in each linked claim.

6 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In mice lacking AMPK in the liver, blood glucose was comparable to wild type and the hypoglycaemic effect of metformin was maintained; metformin-induced inhibition of glucose production was amplified in both AMPK- and LKB1-deficient hepatocytes.

    Liver-specific AMPK-deficient mouse hepatocytes in the 2010 study → Hepatic glucose production / endogenous glucose production source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/metformin-research/20577053.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14", "start_char": 0, "end_char": 1707, "text_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14"}
    experimental_model
    Liver-specific AMPK-deficient and LKB1-deficient mouse hepatocytes with PGC-1alpha overexpression
    exposure
    Metformin dose-response in hepatocytes lacking AMPK or LKB1
    limitations
    A direct challenge to the AMPK requirement. The measured correlate is intracellular ATP, so this is an energy-state mechanism rather than a signalling one.
    nutrient_topic
    Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin
    organism
    Mouse
    plain_language
    Removing the sensor did not remove the drug effect, and in these cells it made it larger.
    primary_references
    [metformin-p20577053] Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. (2010). https://pubmed.ncbi.nlm.nih.gov/20577053/ DOI: 10.1172/jci40671
    tissue_or_cell_type
    Liver
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 593–604

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Liver-specific AMPK-deficient and LKB1-deficient mouse hepatocytes with PGC-1alpha overexpression · source_derived_draft · unverified_draft

    ### metformin-ampk-independent-glucose In mice lacking AMPK in the liver, blood glucose was comparable to wild type and the hypoglycaemic effect of metformin was maintained; metformin-induced inhibition of glucose production was amplified in both AMPK- and LKB1-deficient hepatocytes. Condition category: machinery_impairment nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: Removing the sensor did not remove the drug effect, and in these cells it made it larger. organism: Mouse tissue_or_cell_type: Liver experimental_model: Liver-specific AMPK-deficient and LKB1-deficient mouse hepatocytes with PGC-1alpha overexpression limitations: A direct challenge to the AMPK requirement. The measured correlate is intracellular ATP, so this is an energy-state mechanism rather than a signalling one. exposure: Metformin dose-response in hepatocytes lacking AMPK or LKB1 evidence_span: {"source_cache": "artifacts/metformin-research/20577053.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14", "start_char": 0, "end_char": 1707, "text_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14"} [metformin-p20577053] Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. (2010). https://pubmed.ncbi.nlm.nih.gov/20577053/ DOI: 10.1172/jci40671
    Complete structured claim and evidence

  2. Using an AMPK inhibitor, AMPK activation was found to be required for the inhibitory effect of metformin on glucose production by hepatocytes.

    AMP-activated protein kinase complexes → Hepatic glucose production / endogenous glucose production source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/metformin-research/11602624.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "86e283289def8a6e3e3098d49f321dbcca9a6cd4677ba84f26daf17467179237", "start_char": 0, "end_char": 1390, "text_sha256": "86e283289def8a6e3e3098d49f321dbcca9a6cd4677ba84f26daf17467179237"}
    experimental_model
    Rat hepatocytes, isolated rat skeletal muscle and metformin-treated rats with an AMPK inhibitor
    exposure
    Metformin in hepatocytes and in vivo; compound C AMPK inhibition
    limitations
    The inhibitor experiment supports a requirement for AMPK in these hepatocytes; later work in AMPK-deficient mice reached a different conclusion, recorded separately.
    nutrient_topic
    Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin
    organism
    Rat
    plain_language
    In this experiment, blocking the sensor removed the drug effect on glucose output.
    primary_references
    [metformin-p11602624] Role of AMP-activated protein kinase in mechanism of metformin action. (2001). https://pubmed.ncbi.nlm.nih.gov/11602624/ DOI: 10.1172/jci13505
    tissue_or_cell_type
    Liver and skeletal muscle

    Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 554–565

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Rat hepatocytes, isolated rat skeletal muscle and metformin-treated rats with an AMPK inhibitor · source_derived_draft · unverified_draft

    ### metformin-ampk-required-hepatocyte Using an AMPK inhibitor, AMPK activation was found to be required for the inhibitory effect of metformin on glucose production by hepatocytes. Condition category: normal nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: In this experiment, blocking the sensor removed the drug effect on glucose output. organism: Rat tissue_or_cell_type: Liver and skeletal muscle experimental_model: Rat hepatocytes, isolated rat skeletal muscle and metformin-treated rats with an AMPK inhibitor limitations: The inhibitor experiment supports a requirement for AMPK in these hepatocytes; later work in AMPK-deficient mice reached a different conclusion, recorded separately. exposure: Metformin in hepatocytes and in vivo; compound C AMPK inhibition evidence_span: {"source_cache": "artifacts/metformin-research/11602624.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "86e283289def8a6e3e3098d49f321dbcca9a6cd4677ba84f26daf17467179237", "start_char": 0, "end_char": 1390, "text_sha256": "86e283289def8a6e3e3098d49f321dbcca9a6cd4677ba84f26daf17467179237"} [metformin-p11602624] Role of AMP-activated protein kinase in mechanism of metformin action. (2001). https://pubmed.ncbi.nlm.nih.gov/11602624/ DOI: 10.1172/jci13505
    Complete structured claim and evidence

  3. Metformin significantly reduced fasting hepatic glucose production from 12.9 to 11.0 micromol/kg/min but did not enhance total body glucose disposal during insulin stimulation.

    Metformin → Hepatic glucose production / endogenous glucose production source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/metformin-research/8923861.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "164b296465a3d5730d3dba4c66062ce97c227e61b866b6a42c5beb772f51d688", "start_char": 0, "end_char": 3516, "text_sha256": "164b296465a3d5730d3dba4c66062ce97c227e61b866b6a42c5beb772f51d688"}
    experimental_model
    Randomised double-blind placebo-controlled trial with tracer infusions and euglycaemic clamp
    exposure
    15 weeks of metformin versus placebo in 20 people with type 2 diabetes
    limitations
    Tracer measurement of where the glucose effect comes from. Lactate turnover was measured directly and did not change, which bears on lactate safety questions.
    nutrient_topic
    Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin
    organism
    Human
    plain_language
    In people, the drug works by making the liver release less glucose, not by improving uptake.
    primary_references
    [metformin-p8923861] Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. (1996). https://pubmed.ncbi.nlm.nih.gov/8923861/ DOI: 10.1210/jcem.81.11.8923861
    tissue_or_cell_type
    Liver and whole body

    Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 1386–1397

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomised double-blind placebo-controlled trial with tracer infusions and euglycaemic clamp · source_derived_draft · unverified_draft

    ### metformin-human-hgp-reduction Metformin significantly reduced fasting hepatic glucose production from 12.9 to 11.0 micromol/kg/min but did not enhance total body glucose disposal during insulin stimulation. Condition category: normal nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: In people, the drug works by making the liver release less glucose, not by improving uptake. organism: Human tissue_or_cell_type: Liver and whole body experimental_model: Randomised double-blind placebo-controlled trial with tracer infusions and euglycaemic clamp limitations: Tracer measurement of where the glucose effect comes from. Lactate turnover was measured directly and did not change, which bears on lactate safety questions. exposure: 15 weeks of metformin versus placebo in 20 people with type 2 diabetes evidence_span: {"source_cache": "artifacts/metformin-research/8923861.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "164b296465a3d5730d3dba4c66062ce97c227e61b866b6a42c5beb772f51d688", "start_char": 0, "end_char": 3516, "text_sha256": "164b296465a3d5730d3dba4c66062ce97c227e61b866b6a42c5beb772f51d688"} [metformin-p8923861] Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. (1996). https://pubmed.ncbi.nlm.nih.gov/8923861/ DOI: 10.1210/jcem.81.11.8923861
    Complete structured claim and evidence

  4. Knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats produced a phenotype akin to chronic metformin treatment and abrogated metformin-mediated increases in cytosolic redox state and inhibition of endogenous glucose production.

    Antisense-oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats → Hepatic glucose production / endogenous glucose production source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/metformin-research/24847880.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b", "start_char": 0, "end_char": 1499, "text_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b"}
    experimental_model
    Rat antisense-oligonucleotide knockdown, whole-body knockout mice and hepatic redox measurements
    exposure
    Acute and chronic low-dose metformin; mGPD knockdown and knockout
    limitations
    A redox-shuttle mechanism established in rodents at low doses; it does not by itself exclude complex I or AMPK contributions in other tissues.
    nutrient_topic
    Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin
    organism
    Rat and mouse
    plain_language
    Removing the enzyme both copied the drug and left it nothing further to do.
    primary_references
    [metformin-p24847880] Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. (2014). https://pubmed.ncbi.nlm.nih.gov/24847880/ DOI: 10.1038/nature13270
    tissue_or_cell_type
    Liver
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 502–513

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Rat antisense-oligonucleotide knockdown, whole-body knockout mice and hepatic redox measurements · source_derived_draft · unverified_draft

    ### metformin-mgpd-knockdown-phenocopy Knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats produced a phenotype akin to chronic metformin treatment and abrogated metformin-mediated increases in cytosolic redox state and inhibition of endogenous glucose production. Condition category: machinery_impairment nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: Removing the enzyme both copied the drug and left it nothing further to do. organism: Rat and mouse tissue_or_cell_type: Liver experimental_model: Rat antisense-oligonucleotide knockdown, whole-body knockout mice and hepatic redox measurements limitations: A redox-shuttle mechanism established in rodents at low doses; it does not by itself exclude complex I or AMPK contributions in other tissues. exposure: Acute and chronic low-dose metformin; mGPD knockdown and knockout evidence_span: {"source_cache": "artifacts/metformin-research/24847880.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b", "start_char": 0, "end_char": 1499, "text_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b"} [metformin-p24847880] Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. (2014). https://pubmed.ncbi.nlm.nih.gov/24847880/ DOI: 10.1038/nature13270
    Complete structured claim and evidence

  5. These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice.

    Whole-body mitochondrial glycerophosphate dehydrogenase knockout mice → Hepatic glucose production / endogenous glucose production source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/metformin-research/24847880.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b", "start_char": 0, "end_char": 1499, "text_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b"}
    experimental_model
    Rat antisense-oligonucleotide knockdown, whole-body knockout mice and hepatic redox measurements
    exposure
    Acute and chronic low-dose metformin; mGPD knockdown and knockout
    limitations
    A redox-shuttle mechanism established in rodents at low doses; it does not by itself exclude complex I or AMPK contributions in other tissues.
    nutrient_topic
    Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin
    organism
    Rat and mouse
    plain_language
    A second genetic model gave the same answer.
    primary_references
    [metformin-p24847880] Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. (2014). https://pubmed.ncbi.nlm.nih.gov/24847880/ DOI: 10.1038/nature13270
    tissue_or_cell_type
    Liver
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 515–526

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Rat antisense-oligonucleotide knockdown, whole-body knockout mice and hepatic redox measurements · source_derived_draft · unverified_draft

    ### metformin-mgpd-knockout-replication These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice. Condition category: machinery_impairment nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: A second genetic model gave the same answer. organism: Rat and mouse tissue_or_cell_type: Liver experimental_model: Rat antisense-oligonucleotide knockdown, whole-body knockout mice and hepatic redox measurements limitations: A redox-shuttle mechanism established in rodents at low doses; it does not by itself exclude complex I or AMPK contributions in other tissues. exposure: Acute and chronic low-dose metformin; mGPD knockdown and knockout evidence_span: {"source_cache": "artifacts/metformin-research/24847880.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b", "start_char": 0, "end_char": 1499, "text_sha256": "8378baac19afd12fd3ca66206d079db20e7229a9295414e9678979352e10d92b"} [metformin-p24847880] Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. (2014). https://pubmed.ncbi.nlm.nih.gov/24847880/ DOI: 10.1038/nature13270
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Upper small-intestinal metformin restored SGLT1 expression and glucose sensing in high-fat-diet rats, triggering an SGLT1-dependent pathway that lowered glucose production.

    Metformin → Upper small-intestinal glucose sensing source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/metformin-research/29056513.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a04767b5cd42e2e3e3eced3fc1f6bc2c20d8c71adb044483fe8443ef1c59fc97", "start_char": 0, "end_char": 1110, "text_sha256": "a04767b5cd42e2e3e3eced3fc1f6bc2c20d8c71adb044483fe8443ef1c59fc97"}
    experimental_model
    Rat upper small-intestinal infusion, microbiota transplantation and SGLT1 measurements
    exposure
    Upper small-intestinal metformin in high-fat-diet rats
    limitations
    A regional intestinal mechanism in rats. Transplantation between rats supports the microbial step; human relevance is not established here.
    nutrient_topic
    Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin
    organism
    Rat
    plain_language
    A sensor in the upper gut tells the liver to make less glucose, and the drug restores it.
    primary_references
    [metformin-p29056513] Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway. (2018). https://pubmed.ncbi.nlm.nih.gov/29056513/ DOI: 10.1016/j.cmet.2017.09.019
    tissue_or_cell_type
    Upper small intestine

    Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 970–981

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Rat upper small-intestinal infusion, microbiota transplantation and SGLT1 measurements · source_derived_draft · unverified_draft

    ### metformin-sglt1-sensing Upper small-intestinal metformin restored SGLT1 expression and glucose sensing in high-fat-diet rats, triggering an SGLT1-dependent pathway that lowered glucose production. Condition category: normal nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: A sensor in the upper gut tells the liver to make less glucose, and the drug restores it. organism: Rat tissue_or_cell_type: Upper small intestine experimental_model: Rat upper small-intestinal infusion, microbiota transplantation and SGLT1 measurements limitations: A regional intestinal mechanism in rats. Transplantation between rats supports the microbial step; human relevance is not established here. exposure: Upper small-intestinal metformin in high-fat-diet rats evidence_span: {"source_cache": "artifacts/metformin-research/29056513.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a04767b5cd42e2e3e3eced3fc1f6bc2c20d8c71adb044483fe8443ef1c59fc97", "start_char": 0, "end_char": 1110, "text_sha256": "a04767b5cd42e2e3e3eced3fc1f6bc2c20d8c71adb044483fe8443ef1c59fc97"} [metformin-p29056513] Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway. (2018). https://pubmed.ncbi.nlm.nih.gov/29056513/ DOI: 10.1016/j.cmet.2017.09.019
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards